Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,825 shares of the biopharmaceutical company’s stock after selling 1,625 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $1,055,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Nordea Investment Management AB raised its stake in Regeneron Pharmaceuticals by 1.5% during the third quarter. Nordea Investment Management AB now owns 4,215 shares of the biopharmaceutical company’s stock worth $1,703,000 after acquiring an additional 64 shares in the last quarter. Morgan Stanley raised its stake in Regeneron Pharmaceuticals by 70.6% during the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after acquiring an additional 192,236 shares in the last quarter. Meeder Asset Management Inc. raised its stake in Regeneron Pharmaceuticals by 59.8% during the fourth quarter. Meeder Asset Management Inc. now owns 12,975 shares of the biopharmaceutical company’s stock worth $4,846,000 after acquiring an additional 4,858 shares in the last quarter. Nachman Norwood & Parrott Inc acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $1,778,000. Finally, Boston Advisors LLC raised its stake in Regeneron Pharmaceuticals by 108.9% during the fourth quarter. Boston Advisors LLC now owns 16,708 shares of the biopharmaceutical company’s stock worth $6,240,000 after acquiring an additional 8,710 shares in the last quarter. 66.87% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total value of $734,310.00. Following the sale, the director now directly owns 14,114 shares in the company, valued at $5,786,740. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Christopher R. Fenimore sold 1,848 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total value of $663,376.56. Following the completion of the sale, the vice president now owns 9,871 shares in the company, valued at $3,543,392.87. The disclosure for this sale can be found here. Insiders sold 134,754 shares of company stock valued at $55,439,356 in the last ninety days. 12.42% of the stock is currently owned by insiders.
Several brokerages have commented on REGN. BidaskClub downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Jaffray Companies boosted their target price on Regeneron Pharmaceuticals to $487.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Guggenheim downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, Oppenheimer boosted their target price on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research note on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $413.76.
Regeneron Pharmaceuticals stock opened at $414.47 on Friday. Regeneron Pharmaceuticals Inc has a 1 year low of $281.89 and a 1 year high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.47 and a quick ratio of 3.67. The company has a market capitalization of $45.29 billion, a PE ratio of 20.93, a PEG ratio of 1.68 and a beta of 1.20.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the firm posted $5.23 earnings per share. The firm’s revenue was up 21.9% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2019/03/17/regeneron-pharmaceuticals-inc-regn-shares-sold-by-connor-clark-lunn-investment-management-ltd.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: How to trade on quiet period expirations
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.